TY - JOUR
T1 - Emerging targets in gastroesophageal adenocarcinoma
T2 - what the future looks like
AU - Petrillo, Angelica
AU - Smyth, Elizabeth C.
AU - van Laarhoven, Hanneke W. M.
N1 - Publisher Copyright: © The Author(s), 2023.
PY - 2023/1/1
Y1 - 2023/1/1
N2 - Gastroesophageal adenocarcinoma (GEA) is a heterogeneous disease with a poor prognosis. Chemotherapy has been the cornerstone in treating metastatic diseases. Recently, the introduction of immunotherapy demonstrated improved survival outcomes in localized and metastatic diseases. Beyond immunotherapy, several attempts were made to improve patient survival by understanding the molecular mechanisms of GEA and several molecular classifications were published. In this narrative review, we will discuss emerging targets in GEA, including fibroblast growth factor receptor and Claudin 18.2, as well as the accompanying drugs. In addition, novel agents directed against well-known targets, such as HER2 and angiogenesis, will be discussed, as well as cellular therapies like CAR-T and SPEAR-T cells.
AB - Gastroesophageal adenocarcinoma (GEA) is a heterogeneous disease with a poor prognosis. Chemotherapy has been the cornerstone in treating metastatic diseases. Recently, the introduction of immunotherapy demonstrated improved survival outcomes in localized and metastatic diseases. Beyond immunotherapy, several attempts were made to improve patient survival by understanding the molecular mechanisms of GEA and several molecular classifications were published. In this narrative review, we will discuss emerging targets in GEA, including fibroblast growth factor receptor and Claudin 18.2, as well as the accompanying drugs. In addition, novel agents directed against well-known targets, such as HER2 and angiogenesis, will be discussed, as well as cellular therapies like CAR-T and SPEAR-T cells.
KW - CAR-T cell
KW - Claudin 18.2
KW - FGFR
KW - SPEAR-T
KW - target therapy
KW - trastuzumab deruxtecan
UR - http://www.scopus.com/inward/record.url?scp=85159107134&partnerID=8YFLogxK
U2 - https://doi.org/10.1177/17588359231173177
DO - https://doi.org/10.1177/17588359231173177
M3 - Review article
C2 - 37197225
SN - 1758-8340
VL - 15
JO - Therapeutic advances in medical oncology
JF - Therapeutic advances in medical oncology
ER -